Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 31, 2026 20:51 ET | Source: Robbins LLP

Did You Lose Money Investing in Atara Biotherapeutics, Inc.? Robbins LLP Encourages Investors with Significant Losses to Contact the Firm About Their Rights Against ATRA

Robbins LLP is Investigating Allegations that Atara Biotherapeutics, Inc. (ATRA) Misled Investors Regarding its Drug Candidate
March 31, 2026 15:08 ET | Source: Robbins LLP

AQST Stockholders Have Rights – If You Lost Money Investing in Aquestive Therapeutics, Inc. Contact the Firm for Information About Recovering Your Losses

Robbins LLP is Investigating Allegations that Aquestive Therapeutics, Inc. (AQST) Misled Investors Regarding Approval of Anaphylm
March 31, 2026 14:50 ET | Source: Robbins LLP

NKTR Stockholders Have Rights – If You Lost Money Investing in Nektar Therapeutics Contact Robbins LLP for Information About Recovering Your Losses

Robbins LLP is Investigating Allegations that Nektar Therapeutics (NKTR) Overstated the Prospects of its REZOLVE-AA Trial
March 30, 2026 12:41 ET | Source: Robbins LLP

IBRX Class Action Reminder: Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the ImmunityBio, Inc. Securities Fraud Class Action

Robbins LLP is Investigating Allegations that ImmunityBio, Inc. (IBRX) Misled Investors Regarding its Lead Product Candidate
March 11, 2026 19:54 ET | Source: Robbins LLP

Soleno Therapeutics, Inc. Class Action Notice: Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the SLNO Class Action

Robbins LLP is Investigating Allegations that Soleno Therapeutics(SLNO) Misled Investors Regarding the Viability and Efficacy of its Phase 3 Clinical Trial
March 09, 2026 12:23 ET | Source: Robbins LLP

AQST Class Action Notice: Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the Aquestive Therapeutics, Inc. Class Action Lawsuit

Robbins LLP is Investigating Allegations that Aquestive Therapeutics, Inc. (AQST) Misled Investors Regarding Approval of Anaphylm
March 05, 2026 15:17 ET | Source: Robbins LLP

Robbins LLP Urges INO Stockholders Who Lost Money Investing in Inovio Pharmaceuticals, Inc. to Contact the Firm for Information About Leading the Class Action

Robbins LLP is Investigating Allegations that Inovio Pharmaceuticals, Inc. (INO) Misled Investors Regarding Approval for its CELLECTRA Device
February 18, 2026 14:11 ET | Source: Robbins LLP

Stockholders Who Lost Money Investing in Mereo BioPharma Group plc Should Contact Robbins LLP for Information About Recovering Their Losses from MREO

Robbins LLP is Investigating Allegations that Mereo BioPharma Group plc (MREO) Misled Investors Regarding Phase 3 Orbit and Cosmic Studies for Setrusumab
February 18, 2026 14:07 ET | Source: Robbins LLP

Stockholders Who Lost Money Investing in Ultragenyx Pharmaceutical Inc. Should Contact Robbins LLP for Information About Recovering Their Losses from RARE

Robbins LLP is Investigating Allegations that Ultragenyx Pharmaceutical Inc. (RARE) Misled Investors Regarding Phase III Orbit and Cosmic Studies
February 13, 2026 14:56 ET | Source: Robbins LLP

INO Class Action Alert: Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the Inovio Pharmaceuticals, Inc. Class Action

Robbins LLP is Investigating Allegations that Inovio Pharmaceuticals, Inc. (INO) Misled Investors Regarding Approval for its CELLECTRA Device